Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations

Open access
Martin, Natasha K., Vickerman, Peter, Miners, Alec, Foster, Graham R., Hutchinson, Sharon J., Goldberg, David J., Hickman, Matthew·2012·Hepatology

Abstract

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon–α + ribavirin) has been shown to be cost–effective for patients with no reinfection risk. We examined the cost–effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non–IDUs or no treatment. A dynamic model of HCV transmission and disease progression was developed, incorporating: a fixed number of antiviral treatments allocated at the mild HCV stage over 10 years, no retreatment after treatment failure, potential reinfection, and three baseline IDU HCV chronic prevalence scenarios (20%, 40%, and 60%). We performed a probabilistic cost–utility analysis estimating long–term costs and outcomes measured in quality adjusted life years (QALYs) and calculating the incremental cost–effectiveness ratio (ICER) comparing treating IDUs, ex/non–IDUs, or no treatment. Antiviral treatment for IDUs is the most cost–effective option in the 20% and 40% baseline chronic prevalence settings, with ICERs compared with no treatment of £521 and £2,539 per QALY saved, respectively. Treatment of ex/non–IDUs is dominated in these scenarios. At 60% baseline prevalence, treating ex/non–IDUs is slightly more likely to be the more cost–effective option (with an ICER compared with no treatment of £6,803), and treating IDUs dominated due to high reinfection. A sensitivity analysis indicates these rankings hold even when IDU sustained viral response rates as compared with ex/non–IDUs are halved. Conclusion : Despite the possibility of reinfection, the model suggests providing antiviral treatment to IDUs is the most cost–effective policy option in chronic prevalence scenarios less than 60%. Further research on how HCV treatment for injectors can be scaled up and its impact on prevalence is warranted. (Hepatology 2012)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.24656

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 221

Metadata

Authors
Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M.
Venue
Hepatology
Published
2012-01
Volume
55
Issue
1
Pages
49-57
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2011437704
Cited by
221
References
2
FWCI
12.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations. https://app.cochat.ai/papers/10.1002/hep.24656
The paper
Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M. (2012). Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations. Hepatology. https://doi.org/10.1002/hep.24656

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.